"If (it) can be repeated in a larger number of people, this test will give us an insight into changes occurring in the brain that relate to Alzheimer's disease", said Mark Dallas, a lecturer in Cellular and Molecular Neuroscience at Britain's University of Reading.
One of the big challenges now facing many Alzheimer's researchers is the difficulty in diagnosing the disease during its early, preclinical stages.
Using high-tech mass spectrometry technology, known as IP-MS, scientists identified patients with the rogue peptide in their blood plasma, indicating a build-up of beta-amyloid in the brain, with 90 per cent accuracy.
The current methods for detecting amyloids-positron emission tomography (PET) imaging of the brain and measurement of the clumping protein amyloid-β in cerebrospinal fluid-are expensive and invasive.
BT to hire 3000 engineers to establish faster United Kingdom broadband
BT Openreach has pledged to bring ultrafast broadband to three million households by 2020, according to BBC News . Full-fibre connections are not hampered by distance and can provide speeds up to 1 gigabit a second.
But the breakthrough by the University of Melbourne's Florey Institute of Neuroscience and Mental Health will mean diagnosing the disease will become far easier.
The idea behind the test is to predict the presence and levels of amyloid beta in a person's brain.
It can be detected with brain scans, but these are expensive and impractical.
This is why there is a huge amount of research into tests for Alzheimer's.
Dr Brenda Fitzgerald resigns as CDC Director
But Fitzgerald's departure comes at the height of a deadly flu outbreak and worries that the agency is vulnerable to budget cuts. In an email to NBC News after Fitzgerald resigned, Painter called the stock purchases "an obvious conflict of interest".
"I can see in the future, five years from now, where people have a regular check-up every five years after age 55 or 60 to determine whether they are on the Alzheimer's pathway or not, " Professor Masters said. None of the three drugs now on the market treat the underlying disease.
However, it could be useful in clinical trials.
"This is not a blood test for dementia that people who are anxious about their memory and concentration should be asking their doctors about", said Rob Howard, professor of old age psychiatry at University College London, who was not involved in the study.
So while we don't have any effective singular treatment for Alzheimer's now, this blood test will hopefully speed up research by making clinical trials more effective.
Kate and William dine with Swedish royals
Prince George 's parents also got to try some warm, non-alcoholic glögg as they sipped from a flask to combat the cold (below). William thanked the couple for hosting them during the speech - and invited them to visit the United Kingdom soon, too .
Alzheimer's disease affects over 5 million people in the United States, where the estimated cost of caring for Alzheimer patients in 2017 was $259 billion. "Due to the long time-spans involved, pharmaceutical companies require accurate predictions of who is most at risk".